Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.34 |
| ▸ | HTR2A | P28223 | 5/20 | 0.34 |
| ▸ | DRD2 | P14416 | 4/20 | 0.34 |
| ▸ | HTR7 | P34969 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CCNH | P51946 | 1/20 | 0.32 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | SDHB | P21912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178209 | 0.88 | RXFP1 (0.34) | HTR6HTR2ADRD2HTR7BRD4 | |
| SCHEMBL21178210 | 0.87 | BRD4 (0.45) | HTR6HTR2ADRD2HTR7BRD4 | |
| SCHEMBL30549101 | 0.87 | BRD4 (0.45) | HTR6HTR2ADRD2HTR7BRD4 | |
| SCHEMBL21178237 | 0.82 | HTR6 (0.33) | HTR6HTR2ADRD2HTR7CDK7 | |
| SCHEMBL21178510 | 0.82 | HTR6 (0.33) | HTR6HTR2ADRD2HTR7CDK7 | |
| SCHEMBL21178230 | 0.80 | CDK7 (0.42) | HTR6HTR2ADRD2HTR7CDK7 | |
| SCHEMBL21179249 | 0.79 | CCNK (0.49) | CDK7CCNHMNAT1 | |
| SCHEMBL24588114 | 0.78 | PIK3CA (0.41) | HTR6DRD2EGFR | |
| SCHEMBL26967483 | 0.77 | HTR6 (0.53) | HTR6HTR2ADRD2HTR7EGFR | |
| SCHEMBL24087399 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2021-12-09 | — | — | US | disclosed |
| EP-3740207-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| WO-2019143719-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143719-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | CDK7, CDK3, CCNK | HTR6 3385/4885HTR2A 4559/4885DRD2 4697/4885 |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNK | HTR6 3385/4885HTR2A 4559/4885DRD2 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.